Search the site

News & Events

New study examines vacccine to prevent cervical cancer

The Telethon Institute for Child Health Research today announced a new study investigating a vaccine to prevent infection of Human Papilloma Virus (HPV).

News & Events

Study finds folate protects against childhood brain tumours

A national study led by Perth's Telethon Institute has found that folic acid supplements before and during pregnancy reduces the risk of childhood brain tumours

News & Events

Researchers unlock potential new cancer weapon

In an exciting breakthrough for cancer treatment, a new weapon to enable the immune system to combat the disease may have been unlocked.

News & Events

Global war on brain cancer

Dr Nick Gottardo and Dr Raelene Endersby from The Kids Research Institute Australia are the driving force behind an innovative, global action group on child brain cancer.

Research

Pediatric meningioma: Current approaches and future direction

With improvement in leukemia therapy, central nervous system (CNS) tumors are the leading cause of cancer mortality in children and the most expensive...

Research

Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth

Anti-cancer chemotherapy can be simultaneously lymphodepleting and immunostimulatory.

People

Associate Professor Raelene Endersby

Co-Head, Brain Tumour Research

Research

Challenges to curing primary brain tumours

The seven key challenges summarized in this Position Paper are intended to serve as foci for future research and investment in brain tumours

Research

The Australian and New Zealand Children's Haematology/Oncology Group Biobanking Network

The ANZCHOG-BN was developed to improve and streamline access to high quality pediatric and adolescent/young adult cancer biospecimens for cancer research

Research

Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma

Bevacizumab is well tolerated and appears most effective for rapid tumor control to preserve vision and improve morbidity